Equities Analysts Issue Forecasts for CVRx Q1 Earnings

CVRx, Inc. (NASDAQ:CVRX) – Research analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for CVRx in a note issued to investors on Tuesday, April 8th. William Blair analyst M. Andrew now anticipates that the company will post earnings of ($0.71) per share for the quarter, down from their previous forecast of ($0.64). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx’s Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.23) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.37) EPS and FY2026 earnings at ($2.11) EPS.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group dropped their price target on CVRx from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, April 8th. Lake Street Capital decreased their price target on shares of CVRx from $19.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, April 8th. Piper Sandler boosted their price target on shares of CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Finally, Craig Hallum increased their price objective on shares of CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.83.

CVRx Trading Down 3.9 %

Shares of CVRX stock opened at $6.23 on Friday. CVRx has a 12-month low of $5.87 and a 12-month high of $18.55. The firm’s 50 day moving average is $12.20 and its 200 day moving average is $12.86. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $162.20 million, a P/E ratio of -2.32 and a beta of 1.34.

CVRx (NASDAQ:CVRX) last posted its earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%.

Institutional Trading of CVRx

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its stake in CVRx by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company’s stock worth $49,000 after acquiring an additional 1,186 shares during the last quarter. GAMMA Investing LLC raised its holdings in CVRx by 1,469.3% in the 1st quarter. GAMMA Investing LLC now owns 4,598 shares of the company’s stock valued at $56,000 after buying an additional 4,305 shares during the period. Quarry LP acquired a new position in CVRx in the fourth quarter valued at about $69,000. MetLife Investment Management LLC purchased a new position in CVRx during the fourth quarter worth about $111,000. Finally, Wells Fargo & Company MN increased its position in shares of CVRx by 86.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,894 shares of the company’s stock valued at $113,000 after acquiring an additional 4,115 shares during the last quarter. Institutional investors and hedge funds own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.